Skip to content

Fenosha study

Evaluating the effectiveness of a herbal product (Fenosha) as add-on therapy in uncontrolled epileptic patients: a randomized, double blinded, placebo controlled study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120703010178N17
Enrollment
60
Registered
2019-03-05
Start date
2018-08-06
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy. Epilepsy and recurrent seizures

Interventions

Intervention 1: Intervention group: Fenosha group (herbal product) It contains two gums called dorema ammoniacum and ferula persica, mixed in capsules with a ratio of 70 to 30 to a final weight of 50

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age older than 15 years old Take one or two anti-epileptic drugs at least 2 months before entering the study At least 1 seizure per month for 3 consecutive months Patient agrees to enter the study

Exclusion criteria

Exclusion criteria: Simple partial epilepsy without motor symptoms Known and progressive neurological disorder Status or cluster epilepsy within 3 months before entering the study History of psychogenic epilepsy in the last 2 years Uncontrolled illness or drug use associated with impaired Lab data (liver enzyme at least twice upper limit of normal or Creatinine clearance less than 50 ml / min) Non compliance Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
Seizure frequency. Timepoint: 30, 60, 90 days. Method of measurement: Patient and families's remarks.

Secondary

MeasureTime frame
Safety and adverse drug reactions. Timepoint: 30, 60, 90 days. Method of measurement: Patient's remarks.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sistanizad

Shahid Beheshti University of Medical Sciences

sistanizadm@sbmu.ac.ir+98 21 8820 0087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026